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ARTICLE
FAM222A encodes a protein which accumulates in
plaques in Alzheimer’s disease
Tingxiang Yan1,80, Jingjing Liang2,80*, Ju Gao 1,80, Luwen Wang1,80, Hisashi Fujioka3, The Alzheimer Disease
Neuroimaging Initiative, Xiaofeng Zhu2* & Xinglong Wang1*
Alzheimer’s disease (AD) is characterized by amyloid plaques and progressive cerebral
atrophy. Here, we report FAM222A as a putative brain atrophy susceptibility gene. Our cross-
phenotype association analysis of imaging genetics indicates a potential link between
FAM222A and AD-related regional brain atrophy. The protein encoded by FAM222A is pre-
dominantly expressed in the CNS and is increased in brains of patients with AD and in an AD
mouse model. It accumulates within amyloid deposits, physically interacts with amyloid-β
(Aβ) via its N-terminal Aβ binding domain, and facilitates Aβ aggregation. Intracerebroven-
tricular infusion or forced expression of this protein exacerbates neuroinflammation and
cognitive dysfunction in an AD mouse model whereas ablation of this protein suppresses the
formation of amyloid deposits, neuroinflammation and cognitive deficits in the AD mouse
model. Our data support the pathological relevance of protein encoded by FAM222A in AD.
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A lzheimer’s disease (AD), the leading cause of dementianamed for Dr. Alois Alzheimer, is characterized bypathologic hallmarks amyloid plaques and neurofibrillary
tangles, and accompanied by other prominent pathological
changes such as progressive atrophy of the brain, neuropil
threads, dystrophic neurites, granulovacuolar degeneration, Hir-
ano bodies, and cerebrovascular amyloid1. Amyloid plaques are
spherical extracellular lesions composed of amyloid-β (Aβ) pep-
tides, whereas neurofibrillary tangles are intracellular lesions
made up of hyperphosphorylated form of the microtubule-
associated protein tau. Although many risk factors such as aging,
lifestyle, and environmental factors are usually considered for the
pathogenesis, AD is increasingly proposed to be a genetically
dichotomous disease in the early-onset familial form showing
classical Mendelian inheritance with little influence from the
environment (EOAD), or in the late-onset sporadic form inher-
ited in a non-Mendelian fashion (LOAD)2.
Less than 10% of AD cases are EOAD with only a small
fraction caused by autosomal dominantly inherited genetic
changes in amyloid precursor protein (APP), presenilin 1 (PS1)
or presenilin 2 (PS2), all of which are responsible for the over-
production of Aβ and the earlier formation of amyloid plaques3.
Though more than 90% of AD cases are LOAD referred to as
sporadic AD without family history, they have the similar clinical
and pathologic phenotypes as EOAD and are heritable4. In the
past decade, intensive efforts have been made to identify over 25
genes associated with AD5. In support of the dominant amyloid
cascade hypothesis suggesting Aβ deposition in the brain as the
primary cause, a number of AD-associated genes are enriched in
the APP processing pathway, and involved in Aβ overproduction
and amyloid plaque deposition though their encoded proteins are
usually not directly associated with amyloid plaques.
Quantitative structural magnetic resonance imaging (MRI) has
been extensively used for assessment of AD-related structural
differences in selective brain regions6. Genome-wide association
studies (GWAS) using MRI measures have identified several AD
risk variants7,8. Likewise, the MRI changes in statistically-defined
regions of interest (ROI) were found closely associated with
reported AD risk variants9,10. Genetic loci harboring variants can
be associated with multiple, sometimes seemingly distinct,
traits11,12. The test for such associations, i.e., cross-phenotype
association test, has been increasingly employed to investigate the
genetic overlap between multiple traits and diseases. Our previous
study has developed a cross-phenotype association analysis
(CPASSOC) that can integrate association evidence from
GWAS summary statistics of multiple traits, either correlated,
independent, continuous, or binary traits, and has been success-
fully used to identify four loci associated with hypertension-
related traits missed by a single-trait analysis13. In this study, we
performed CPASSOC analysis of MRI measures and genetic
datasets, and identified a possible link between FAM222A and
AD-related regional brain atrophy. To understand its pathological
role in AD, we investigated the protein encoded by FAM222A in
patients with AD or transgenic mice for AD, and found its
characteristic accumulation within the center of amyloid deposits.
Further mechanistic study revealed that this protein could phy-
sically interact with Aβ and regulate Aβ aggregation and amyloid
formation. Our results therefore identify a protein that likely
plays an important role in amyloidosis, a finding providing per-
spective for AD pathogenesis.
Results
Susceptibility of regional brain atrophy to FAM222A in AD.
To identify brain atrophy-related imaging quantitative trait loci,
we employed a genome-wide whole brain approach to analyze the
imaging genetic dataset from the Alzheimer’s Disease Neuroi-
maging Initiative (ADNI) (Supplementary Fig. 1a). After GWAS
and the estimation of shared genetic contributions among 145
ROIs spanning the entire brain by linkage disequilibrium (LD)
regression method14 (Supplementary Fig. 1b, c), we attempted to
extract disease-related ROIs and detect genetic variants associated
with them. With hierarchical clustering analysis on a genetic
correlation network (Supplementary Fig. 1d–k), 16 modules of
ROIs with high within-module genetic correlation were generated
(Supplementary Fig. 1l, m). We further combined GWAS sum-
mary statistics of ROIs in each module using CPASSOC we
developed13. Previously reported AD top markers, APOE single
nucleotide polymorphism (SNP) rs42935815, TOMM40 SNP
rs207565015, APOC1 SNP rs1272105116, and rs117028417 on
FAM222A were found in one module (Fig. 1, Supplementary
Figs. 2, 3 and Supplementary Table 1), which consists of five ROIs
including left hippocampus, right hippocampus, basal forebrain,
entorhinal area, and planum polare, brain areas we know are
affected by AD17–19 and well predict AD (Supplementary Fig. 4).
SNP rs117028417 had a minor allele A (frequency= 0.044) with
positive effects for all 5 ROIs in the ADNI cohort (P= 1.95 ×
10−8 for CPASSOC analysis; Supplementary Table 2), and was
further validated to be associated with the mean volume of hip-
pocampus, one of the earliest affected brain regions in AD, in the
Enhancing NeuroImaging Genetics through Meta-Analysis
(ENIGMA) consortium cohort comprising MRI images of
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Fig. 1 CPASSOC analysis of the ADNI cohort. Manhattan plot of CPASSOC analysis combining GWAS summary statistics of ROIs in the green-colored
module (Supplementary Fig. 1m) including left hippocampus, right hippocampus, basal forebrain, entorhinal area, and planum polare. The red line
represents the threshold of P= 5 × 10−8 for the genome-wide significance level. Arrows indicate loci associated with regional brain atrophy. Source data
are provided as a Source Data file (Source Data for GWAS in Fig. 1).
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30,717 individuals from 50 cohorts20 with the same effect direc-
tion (β= 38.1, P= 8.29 × 10−3; Supplementary Table 2).
On a genome-wide scale, FAM222A rs117028417 was only
marginally associated with AD diagnosis in the International
Genomics of Alzheimer’s Project (I-GAP, P= 0.052)21. The
positron emission tomography (PET) imaging using radiotracer
18F-Florbetapir (AV45) provides quantitative measures of
amyloid pathology in vivo22. To investigate whether SNP
rs117028417 is associated with brain Aβ accumulation, we
performed single SNP association test of rs117028417 with
AV45 standard uptake value ratio (SUVR) measures for brain
regions available in the PET scan dataset from ADNI. The minor
allele A of rs117028417 was found significantly associated with
longitudinal decrease but not baseline of AV45 SUVR measures
in anterior or posterior cingulate (P < 0.0125) (Supplementary
Table 3), which is relatively consistent with the findings from
brain volume associations, where the association direction was
positive (i.e. higher volume). rs117028417 is located in an
intergenic region that is approximately 5 kb downstream of
FAM222A and 8 kb downstream of TRPV4. We searched among
published GWAS studies of AD or AD-related biomarkers and
did not identify common variants previously reported on these
two genes. We thus further performed gene-based burden and
SKAT tests23,24 of coding variants on both FAM222A and
TRPV4. All of the coding variants on these two genes available in
ADNI whole-genome sequencing data were low-frequency or rare
variants with minor allele frequency less than 0.05 (Supplemen-
tary Table 4). FAM222A, but not TRPV4, displayed significant
association with AV45 SUVR longitudinal changes in anterior or
posterior cingulate or lateral parietal regions in the burden test
after adjusting for 10 independent tests (P < 0.005) (Supplemen-
tary Table 5), collectively suggesting a possible role of FAM222A
in brain amyloid deposition. However, when we tested
rs117028417 for genetic association with AD cerebrospinal fluid
(CSF) Aβ and tau biomarkers, only nominal association of
rs117028417 with total tau annual change could be discovered,
and there was no association with baseline CSF Aβ and tau on
both single SNP association tests and variant burden tests
(Supplementary Tables 6, 7), indicating that FAM222A variant
may not have a strong genetic influence on AD biomarkers.
FAM222A-encoded protein accumulates within amyloid pla-
ques. The large independent AD brain imaging dataset including
GWAS studies is not available at this time, making it difficult to
further validate the genetic link between FAM222A and AD-
related brain atrophy. However, to elucidate the possible patho-
logical role of FAM222A in AD, we carried out experimental
validation to focus on its encoded protein, which we designated as
Aggregatin. Aggregatin consists of 452 amino acids with a pre-
dicted molecular weight of 47 kD, and has not yet been char-
acterized. Using a well-characterized specific antibody against
Aggregatin (Supplementary Fig. 5a–e), Aggregatin was found
predominantly expressed in the central nervous system (CNS)
including both the brain and the spinal cord, but not in other
tissues such as heart, spleen, lung, kidney, or liver in mice or
humans (Supplementary Fig. 5d, e). There was a slight increase in
the expression of Aggregatin in brain lysates from AD patients
compared to age-matched control subjects (Supplementary
Fig. 5f–h). The most distinct pattern of Aggregatin immunos-
taining observed in AD was that Aggregatin was remarkably
immunoreactive within the center of amyloid plaques, which
were stained by the pan-Aβ antibodies 6E10 and 4G8, the N-
terminal truncated and modified pyroglutamate Aβ species Aβ
[N3pe] antibody 82E1, fibrillar Aβ dye thioflavin-S (Thio-S) or
oligomer Aβ antibody NU-425 (Fig. 2a, b and Supplementary
Fig. 6a–e). In contrast, all control brain sections lacking detectable
amyloid plaques demonstrated weak diffusive Aggregatin
immunoreactivity without association with puncta (Fig. 2a).
Robust Aggregatin staining of the central core of amyloid
deposits was consistently observed in the brains of multiple
mouse models for AD including 5XFAD26, TgCRND827, APP/
PS128, Tg257629, and 3xTg30 transgenic mice overexpressing
human mutant APP along with or without human mutant PS1
(Fig. 2c, d and Supplementary Fig. 6f–h). With the exception of
5XFAD or Tg2576 mice in which Aggregatin-positive foci were
connected with wispy fibrils, Aggregatin within amyloid deposits
of other transgenic mice showed negligible projecting fibrillar
structures, similar as in human plaques. Despite the general
localization of Aggregatin large puncta to the core of amyloid
deposits, they highly co-localized with Aβ in 5XFAD mice but not
in AD patients or TgCRND8 mice, together indicating that the
processes contributing to amyloid deposition may be different in
human and different animal models. Notably, the formation of
Aggregatin puncta occurred concurrently with amyloid deposi-
tion, but was not present in the pre-depositing young 5XFAD
mice (Supplementary Fig. 6i). The characteristic Aggregatin-
positive core staining was abolished by the pre-absorption of
primary antibodies with human recombinant Aggregatin protein
(rAggregatin) purified by combined 10 K dialysis and size-
exclusion chromatography, but not Aβ1-42 peptides (Supplemen-
tary Fig. 7a), further validating the specificity of the anti-
Aggregatin antibody. To confirm the presence of Aggregatin
within amyloid deposits, we isolated amyloid cores purified by
sucrose density gradient fractionation of 2% sodium dodecyl
sulfate (SDS) homogenized AD or 5XFAD mouse brains. Dot blot
and immunoblot studies of proteins under native and denatured
forms respectively confirmed the existence of full-length
Aggregatin without noticeable cleaved products in the SDS-
resistant insoluble core-enriched fractions positive for 6E10
(Fig. 2e–h).
Aggregatin physically interacts with Aβ. The radio-
immunoprecipitation assay buffer (RIPA) widely used for co-
immunoprecipitation failed to extract Aggregatin from AD brains
(Supplementary Fig. 7b), making it difficult to examine the likely
association between Aggregatin and Aβ in AD. To overcome this
obstacle, we performed in vitro pull-down assays using synthetic
Aβ1–40 or Aβ1–42 and rAggregatin. Dynamic light scatting (DLS),
circular dichroism (CD), and SDS-PAGE assays of rAggregatin
indicated that rAggregatin existed in the soluble partially folded
monomeric state (Supplementary Fig. 7c–e). Notably, rAggregatin
co-precipitated with different forms of Aβ1–40 or Aβ1–42 (Fig. 3a
and Supplementary Fig. 7f, g). Consistently, immobilized
monomeric Aβ1–40 or Aβ1–42 was also able to pull down rAg-
gregatin (Supplementary Fig. 7h). Further surface binding affinity
assays revealed that immobilized Aβ1–40 or Aβ1–42 bound to
rAggregatin, and similarly, immobilized rAggregatin bound to
Aβ1–40 or Aβ1–42 all within the nanomolar ranges (Fig. 3b, c and
Supplementary Fig. 7i, j). In agreement with these results, surface
plasmon resonance (SPR) measurements confirmed that Aβ1–42
bound to immobilized rAggregatin at the low nanomolar dis-
sociation equilibrium constant (Kd) (Fig. 3d). Although no
measurement was noted in blank or BSA-immobilized sensor
chips (Supplementary Fig. 7k), signal spikes produced in the SPR
assays may be in proportion to the mass of Aβ aggregates, making
dynamic measurements unlikely consistent with the surface
binding affinity assessments at the steady state. To investigate the
binding of rAggregatin to Aβ ex vivo, we performed an in situ
binding assay in which fixed brain sections of AD patients or
5XFAD mice were incubated with Flag-tagged rAggregatin and
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stained by an anti-Flag antibody. Remarkably, all amyloid
deposits were labelled by rAggregatin (Supplementary Fig. 7l–n).
Considering the widespread presence of Aβ in brains, it was not
surprising that brain sections also showed background staining
after rAggregatin incubation. Notably, amyloid deposits and the
background binding of rAggregatin were completely abolished by
pre-incubation of rAggregatin with Aβ1–40 or Aβ1–42 (Supple-
mentary Fig. 7l–n), confirming that rAggregatin binds amyloid
deposits by interacting with Aβ. Collectively, these results high-
light the pathological relevance of Aggregatin in AD, and show
that Aggregatin is a Aβ binding protein with high-affinity.
Aggregatin binds to Aβ via its N-terminal region. Next, we
generated a series of rAggregatin deletion mutants to map the
binding region for Aβ. Although rAggregatin alone does not form
oligomers or aggregates, the composition of Aβ preparations at
the micromolar range quickly changes over time due to the for-
mation of higher order oligomers, which are expected to influence
the Aggregatin and Aβ interaction. To quantitatively identify the
binding strength of different rAggregatin deletion mutants,
the in situ binding assay rather than pull-down assay was used for
the binding motif mapping. The deletion of residues from 1 to 80
(designated as NABD, N-terminal Aβ binding domain), but not
residues outside of this region, was found to greatly reduce the
binding of rAggregatin to amyloid deposits (Fig. 3e–g and Sup-
plementary Fig. 8a, b). Recombinant NABD (rNABD) alone was
able to bind to amyloid deposits or Aβ1–42 similar as full-length
rAggregatin, and caused a dose-dependent decrease in the asso-
ciation between rAggregatin and amyl deposits when co-
incubated (Fig. 3b, c, e–g and Supplementary Fig. 8c, d), toge-
ther suggesting NABD as the domain both necessary and suffi-
cient for Aβ binding. The residues from 61 to 80 appear to be a
core motif for NABD though they alone were not sufficient to
bind amyloid deposits (Fig. 3e–g and Supplementary Fig. 8a, b).
Notably, rNABD bound amyloid deposits in a length-dependent
manner, and rAggregatin with partial deletions of every 5 amino
acids within the core motif of NABD exhibited weaker but still
strong interactions with amyloid deposits (Supplementary Fig. 8a,
b), further indicating that NABD may contain multiple sites
cooperatively involved in Aβ binding.
Aggregatin cross-seeds Aβ via direct binding. Given the strong
interaction between Aggregatin and Aβ, we further set out
to determine whether Aggregatin would influence the Aβ
d
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Fig. 2 Aggregatin accumulates within the center of amyloid deposits. a Representative images of immunohistochemistry of Aggregatin (arrowheads) and
amyloid plaques (stained by the 6E10 antibody) in adjacent sections (denoted by asterisks) of cortices of sporadic AD patients. b Representative
fluorescent images of Aggregatin (Red), amyloid plaques (Green, stained by the 6E10 antibody) and DAPI nuclei staining (Blue) in cortices of sporadic AD.
c Representative images of immunohistochemistry of Aggregatin (arrowheads) and amyloid plaques (stained by the 6E10 antibody) in adjacent sections
(denoted by asterisks) of brains of 6-month-old 5XFAD mice. d Representative images of Aggregatin (Red), amyloid plaques (Green, stained by the 6E10
antibody) and DAPI nuclei staining (Blue) in brains of 6-month-old 5XFAD mice. e, f Representative dot blots of Aggregatin and Aβ (6E10) in serial
fractions of amyloid plaques separated by differential centrifugation in sucrose gradient from sporadic AD patients (e) or 6-month-old 5XFAD mice (f). g, h
Representative immunoblots of Aggregatin and Aβ (6E10) in the SDS-resistant insoluble core-enriched fraction from sporadic AD patients (g) or 6-month-
old 5XFAD mice (h). Arrow heads point Aggregatin. Due to the presence of urea used for plaque core protein extraction, plaque core fractions show slight
shifts compared to SDS soluble fraction. All experiments were independently performed at least three times. Source data are provided as a Source Data file
(Source Data for Statistics and Blots).
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aggregation process. Aβ aggregation kinetics were first monitored
in vitro using Aβ1–40 or Aβ1–42 for the thioflavin T (ThT) based
fluorescence assay. As illustrated by changes in ThT-associated
fluorescence, Aβ self-aggregated only at high concentrations
whereas rAggregatin alone did not produce any observable
aggregate (Fig. 4a and Supplementary Fig. 9a). Remarkably, once
co-incubated with rAggregatin, Aβ was able to form aggregates at
low concentrations even in the nanomolar range (Fig. 4a, b and
Supplementary Fig. 9a–c). With increasing concentrations of
rAggregatin, the lag times of the aggregation reaction were greatly
decreased (Fig. 4a and Supplementary Fig. 9b). As a control,
rAggregatinΔ61–80 had similar folding as wild type rAggregatin,
but failed to induce Aβ1–42 aggregation (Fig. 4a and Supple-
mentary Fig. 7d, e). These observations were confirmed using
immunoblot and dot blot analyses for Aβ aggregation measure-
ments under denatured and native conditions, which showed that
Aggregatin but not rAggregatinΔ61–80 indeed promoted Aβ1–42
oligomerization (Fig. 4c–f and Supplementary Fig. 9d). Of note,
due to the sensitivity of immunoblot, Aβ oligomer was only
detectable with long exposure when Aβ1–42 at the low micromolar
but not nanomolar was applied. Consistently, transmission elec-
tron microscopy analyses revealed that soluble Aβ1–42 proto-
fibrils31 were more abundant and have more complicated
structures in the presence of rAggregatin during the early phase
of incubation when Aβ fibrils were absent (Fig. 4g). As expected,
the low concentration of Aβ1–42 only yielded very few short and
un-branched fibrils after long periods of incubation under
negative staining (Fig. 4g), and rAggregatin alone did not form
identifiable particles or large aggregates (Supplementary Fig. 9e).
Strikingly, co-incubation of low micromolar Aβ1–42 with rAg-
gregatin lead to the formation of large micrometer-long branched
fibrils (Fig. 4g and Supplementary Fig. 9f), which were Thio-S-
positive and visible under the fluorescent microscopy (Fig. 4h).
Taken together, these data imply Aggregatin as a potent seeding
factor for Aβ oligomerization and aggregation.
Aggregatin regulates amyloid deposition. Aβ levels are low in
young especially predepositing 5XFAD mice26. To examine the
effect of extracellular Aggregatin on amyloid deposition with
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unrestricted access to predeposit-state Aβ, we performed intracer-
ebroventricular (ICV) infusion of Flag-tagged rAggregatin or
rAggregatinΔ61–80 into 5XFAD mice at 4-month-old, when Aβ
rises to high levels26 (Supplementary Fig. 10a). Infusion did not
cause the death of mice or histological abnormalities in the brain.
Importantly, the levels of total Aβ, APP or BACE1 remained
unchanged 4 weeks after rAggregatin infusion, indicating that
rAggregatin did not affect Aβ production or degradation (Supple-
mentary Fig. 10b, c). ICV infused rAggregatin was detected in
amyloid deposit (Fig. 5a). Remarkably, compared to age-matched
control mice infused with artificial cerebrospinal fluid (aCSF),
rAggregatin-infused mice showed greatly increased amyloid
deposition spreading the brain at 5 months of age, which could be
completely blocked by the deletion of NABD core motif (Fig. 5b, c
and Supplementary Fig. 10d, e). As prominent AD pathological
features, microgliosis and astrogliosis are closely associated with
amyloid deposits in 5XFAD mice26,32. Corresponding to increased
plaque load, 5XFAD mice infused with rAggregatin but not
rAggregatinΔ61–80 exhibited more microgliosis and astrogliosis
compared to aCSF-infused control 5XFAD mice (Fig. 5d and
Supplementary Fig. 10f). 5XFAD mice begin to show cognitive
deficits at around 4-months-old33,34. Compared with NTG mice,
FAD mice exhibited significantly impaired Y-maze and Barnes-
maze performance, both of which were significantly exacerbated in
transgenic mice with rAggregatin but not rAggregatinΔ61–80
infusion (Fig. 5e, f). To further examine the role of neuronal
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Fig. 5 Aggregatin regulates amyloid deposits. 5-month-old 5xFAD mice were ICV infused with Flag-tagged rAggregatinΔ61–80 or rAggregatin for
4 weeks. a Representative images of Flag-tagged Aggregatin (Red) and amyloid plaques (Green, Thio-S) in the brain. b, c Representative images (b) and
quantification (c) of plaque by NU-4 antibody in the total brain (Total), cortex or hippocampus (n= 18 mice in each group). d Quantification of astrogliosis
and microgliosis in hippocampus (representative images shown in Supplementary Fig. 10f). e, f Y-maze (e) and Barnes maze (f) performance (n= 15, 17,
18, 18, and 18 mice for NTG aCSF, NTG rAggregatin, 5XFAD aCSF, 5XFAD rAggregatinΔ61–80, and 5XFAD rAggregatin respectively). 5-month-old 5XFAD
mice were injected with AAV1-GFP or AAV1-Aggregatin at 1.5 month-old. g, h Representative images (g) and quantification (h) of plaques stained by NU-4
in the hippocampus (n= 18 mice in each group). i Quantification of astrogliosis and microgliosis in the hippocampus (n= 18 mice in each group). j, k Y-
maze (j) and Barnes maze (k) performance (n= 18 mice in each group). Representative images are shown in Supplementary Fig. 11g. 5-month-old 5XFAD
mice were injected with AAV1-shControl or AAV1-shAggregatin at 1.5-month-old. l, m Representative images (h) and quantification (i) of plaques stained
by NU-4 in the hippocampus (n= 18 mice in each group). n Quantification of astrogliosis and microgliosis in the hippocampus (n= 18 mice in each group).
Representative images are shown in Supplementary Fig. 12f. o, p Y-maze (o) and Barnes maze (p) performance (n= 18 mice in each group). Source data
are provided as a Source Data file (Source Data for Statistics and Blots). Data are means ± s.e.m. Student’s t-test or one and two-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparison test. *P < 0.05, #P < 0.05 (relative to aCSF, AAV1-GFP or shControl AAV1), ***P < 0.001, ****P <
0.0001. ns, non-significant.
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Aggregatin in amyloid deposition, we injected adeno-associated
virus serotype 1 encoding human Aggregatin or GFP alone under
the neuron specific promoter eSYN (AAV1-Aggregatin or AAV1-
GFP) into the hippocampus CA1 of young predepositing 5XFAD
mice at 1.5-month-old (Supplementary Fig. 11a). When analyzed at
5 months of age, in line with ICV infusion experiments, intra-
hippocampal injection of AAV1-Aggregatin significantly increased
amyloid deposition without any effect on total Aβ levels in the GFP-
positive hippocampal region, but not in the brain areas without
AAV1-Aggregatin delivery (Fig. 5g, h and Supplementary
Fig. 11b–f), together suggesting that Aggregatin is sufficient to
enhance amyloid deposition in vivo. Consistently, amyloid
deposition associated microgliosis, astrogliosis, and cognitive defi-
cits were also worsened by neuronal Aggregatin overexpression
(Fig. 5i–k and Supplementary Fig. 11g). To investigate whether
Aggregatin was required for amyloid deposition, we performed
intrahippocampal injection of AAV1 co-expressing GFP and a
short hairpin RNA targeting Aggregatin (AAV1-shAggregatin) or
control shRNAi (AAV1-shControl) in predepositing 5XFAD mice
(Supplementary Fig. 5b, c). It was observed that decreasing
Aggregatin was not associated with neuronal loss or altered total Aβ
(Supplementary Fig. 12a). At 5 months of age, the injection of
AAV1-shAggregatin significantly alleviated amyloid deposition in
the GFP-positive areas of hippocampus compared to AAV1-
shControl injection, but not in the GFP-negative brain areas (Fig. 5l,
m and Supplementary Fig. 12b–e). Likewise, Aggregatin reduction
significantly alleviated amyloid deposit associated microgliosis,
astrogliosis, and cognitive impairment (Fig. 5n–p and Supplemen-
tary Fig. 12f). Taken together, these results further imply that
Aggregatin is also an important factor necessary for amyloid
deposition.
Discussion
Here, we report on Aggregatin, the protein encoded by
FAM222A, as a plaque core protein directly binding Aβ and
facilitating Aβ aggregation, a process thought to be central in AD
onset. Therefore, this work provides strong experimental evidence
supporting a pathophysiological role for Aggregatin in AD.
In people diagnosed with AD or mild cognitive impairment
(MCI), a proportion of whom can progress to AD, FAM222A is
associated with the module enriched for atrophy in AD-affected
brain regions. FAM222A association with hippocampal volume
could be validated in the replication ENIGMA cohort, together
pointing to a potential mechanism by which FAM222A may affect
regional brain atrophy. Notably, our cross phenotype association
analysis also led to the identification of long-established AD risk
genes APOE, TOMM40, and APOC1 exclusively in the same
module, suggesting possible genetic interplays between FAM222A
and AD risking genes. Interestingly, although we only discovered
marginal association between rs117028417 and AD diagnosis,
FAM222A, but not the nearby gene TRPB4, was found significantly
associated with longitudinal increase of brain amyloid deposition.
Along this line, as AD is a genetically complex and multifactorial
disease with different etiological subtypes, FAM222A variants or
pathogenic mutations strongly associated with AD may be present
in subsets of AD patients. Nevertheless, although our genetic dis-
covery study did not observe a strong influence of FAM222 variant
on AD risk and biomarkers, the module enriched for FAM222A
and previously reported AD risk variants likely represents a statis-
tical AD-specific cluster worthy of further investigation using
independent AD neuroimaging databases.
Due to the limited sample size, only a slight, but not significant
increase of Aggregatin mRNA level was observed in AD cortices
collected in our laboratory (Supplementary Fig. 13a, b). However,
analysis of previously published microarray data of the Mount
Sinai Brain Bank (MSBB) cohort35 found significantly increased
levels of Aggregatin mRNA in many brain regions especially
cortices of AD, which were also tested to be associated with AD
neuropathologies (Supplementary Fig. 13c, d and Supplementary
Tables 8, 9). DNA methylation is one of several epigenetic
mechanisms regulating gene expression36 and has been impli-
cated in AD37. Interestingly, several methylation sites on
FAM222A associated with AD could be identified (Supplemen-
tary Fig. 14 and Supplementary Table 10), indicating the likely
involvement of FAM222A in AD pathogenesis through epigenetic
regulation of its gene expression. Considering Aggregatin mRNA
levels were usually measured at one time-point, future studies
may be interesting to investigate longitudinal changes of Aggre-
gatin gene expression and their relationship with neuropatholo-
gies during the progression of disease. While the relationship
between FAM222A DNA methylation, transcription, translation,
and posttranslational modification remains to be determined,
these interesting findings provide further genetic evidence sup-
porting the association of FAM222A to AD.
Consistent with the genetic association of FAM222A with
longitudinal brain Aβ deposition, pathologically accumulated
Aggregatin, the protein encoded by FAM222A, is readily noted in
plaques in AD and amyloid deposits in multiple APP transgenic
mice, strongly illustrating the pathological function of Aggregatin.
Of note, there are remarkable differences in the morphology of
Aggregatin puncta and their co-localization with Aβ. Similarly, as
plaques in AD patients are more complex structures than amyloid
deposits in APP transgenic mice38, it could be expected that
Aggregatin is also present differentially in amyloid core-enriched
fractions from AD patients and 5XFAD mice. A number of
explanations may account for the discrepancy regarding the
pattern of Aggregatin puncta or presence of Aggregatin in pla-
ques, including but not limited to differences in disease stages, the
effects of Aβ clearance and degradation pathways or the length of
time spent for plaque deposition. This notion is indeed supported
by the observation that while only one or several condensed
Aggregatin foci were present in single plaque in AD, amyloid
deposits in cortex from patients with Down’s syndrome (DS), a
complex genetic abnormality developing AD-like pathology, were
largely associated with multiple foci (Supplementary Fig. 15).
It is still unclear how Aggregatin becomes accumulated within
the center of plaques without the ability for self-aggregation.
Aggregatin appears to bind Aβ1–40 and Aβ1–42 with different
affinities. Along this line, amyloid plaques are made up of dif-
ferent N or C-terminally truncated and modified Aβ species39.
Interestingly, we found that Aggregatin was present in exosomes
(Supplementary Fig. 16). Although Aggregatin has no signal
sequence and is not predicted to be secreted, this data supports
the possibility that Aggregatin can be exported into the interstitial
fluid. Of note, the presence of exogenously expressed Aggregatin
in exosomes of cultured cells is physiologic. There may be other
mechanisms responsible for Aggregation secretion under patho-
logical conditions. As Aggregatin protein levels were upregulated
in AD, there may be a complex interplay among Aβ specific
forms, Aggregatin expression, post-translational modification,
extracellular secretion, and other unknown factors responsible for
this. Nevertheless, on the basis of the facts that Aggregatin puncta
appear concurrently with amyloid plaques and does not exist in
the predepositing mice, Aggregatin should accumulate in plaques
before or concurrent with rather than after the well formation of
plaques. Aggregatin did not form intraneuronal accumulation in
AD patients and 5XFAD mice. Not surprisingly, we did not
observe the presence of Aggregatin puncta in neurons bearing
neurofibrillary tangles (Supplementary Fig. 17a). Along this line,
intraneuronal APP and/or Aβ immunoreactivity assessed by 6E10
was not changed by Aggregatin in 5XFAD mice. Therefore,
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Aggregatin may not be involved in intraneuronal protein aggre-
gation. Noteworthily, Aggregatin does not physically interact with
tau and other previously reported plaque-associated proteins such
as α-synuclein and APOE (Supplementary Fig. 17b–d), further
implicating the likely specific link between Aggregatin and Aβ.
However, as AD is a multifactorial disease, further detailed
investigation will still be needed to determine the spatiotemporal
relationship between Aggregatin and other AD-related patholo-
gies especially considering the presence of Aggregatin immu-
noreactivity outside of plaques.
Aggregatin facilitates Aβ aggregation in vitro although it is not
clear whether Aggregatin influences the primary or secondary
nucleation. Increasing Aggregatin enhances, whereas reduced
Aggregatin suppresses amyloid deposition and associated neuroin-
flammation and cognitive deficits. Of note, in addition to exacerbate
Aβ pathology in adult 5XFAD mice, Aggregatin infusion causes
further amyloid deposition in aged 5XFAD mice when amyloid
deposit size and number largely plateau (Supplementary Fig. 18).
Therefore, Aggregatin is likely an unrecognized co- or even limiting
factor both necessary and sufficient for Aβ aggregating into the
fibrils to form plaques. Although the bioinformatics analysis of
Aggregatin amino acid sequence reveals that Aggregatin does not
contain any known conserved functional motifs, our CD char-
acterization of Aggregatin indicated it as at least a partially folded
protein containing α-helix, β-sheet, and intrinsically disordered
element(s) (Supplementary Fig. 7e). While the structure and phy-
siological function of Aggregatin is still under investigation, we
found that Aggregatin was exclusively expressed in the CNS. The
substantial loss of Aggregatin in hippocampus does not cause
neuronal death, suggesting that Aggregatin may not be vital for
neuronal survival. Future studies may be feasible to generate mice
with global or neuronal specific deletion of Aggregatin to test
whether the knockout of Aggregatin is sufficient to completely
abolish amyloid deposition and further validate the pathological
role of Aggregatin in amyloid plaque formation and disease
progression.
The genetic inhibition of Aggregatin-Aβ interaction was able to
suppress Aggregatin-induced Aβ aggregation or amyloid deposits,
suggesting that Aggregatin should directly interact with Aβ to
regulate its pathology. Of note, although rNABD (i.e. Aggregatin
1–80 or Aggregatin Δ81–452) alone is able to bind Aβ, it does not
induce Aβ1–42 aggregation or promote amyloid deposits (Sup-
plementary Fig. 19), suggesting that the C-terminal fragment is
also required for Aggregatin-induced Aβ aggregation and plaque
formation. The exact mechanism for Aggregatin-mediated Aβ
aggregation is still under investigation. Noteworthily, likely due to
the high Aβ binding affinity of Aggregatin, the specific anti-
Aggregatin antibody used in this study does not dissociate
the Aggregatin-Aβ interaction or prevent Aggregatin-induced
aggregation of Aβ, and likewise, ICV infusion of the specific anti-
Aggregatin antibody failed to alleviate Aβ pathologies in 5XFAD
mice. Thus, the Aggregatin targeted immunotherapy for AD may
require the generation of high-affinity monoclonal antibodies.
The genetic manipulation or infusion of Aggregatin did not
change APP or Aβ levels, suggesting that Aggregatin is unlikely
involved in Aβ production or degradation. However, even though
Aggregatin large puncta do not overlap with neurons, microglia
or astrocytes, our results cannot rule out the possibility that
Aggregatin may regulate amyloidosis indirectly through neuronal
function or microglial or astrocytic Aggregatin, which is also
worthy of further clarification. APOE4 is the strongest genetic
risk factor for LOAD. Although the involvement of APOE in Aβ
metabolism might complicate the interpretation of data40, future
studies will also be interesting to investigate Aggregatin-mediated
amyloidosis in vivo on the human ApoE knock-in or ApoE
knockout background as previously reported41.
In conclusion, we have reported FAM222A as a likely gene
associated with AD-related regional brain atrophy, which encodes
an amyloid plaque core protein pathologically involved in Aβ
assembly and amyloid deposition. Our findings therefore not only
inform future genetic studies of FAM222A, but also encourage
detailed pathophysiological investigation of its encoded Aggre-
gatin for AD and related dementia.
Methods
Samples, genotyping, and imputation. Data used in the preparation of this article
were obtained from the ADNI database (http://www.loni.ucla.edu/ADNI). The
Illumina SNP genotyping data, demographic information, APOE genotype and
baseline diagnosis information from 754 ADNI-1 participants, including 213
cognitive normal individual controls, 175 AD patients, and 366 patients with mild
cognitive impairment (MCI) were downloaded from ADNI database. All partici-
pants provided written informed consent and study protocols were approved by
participating sites’ Institutional Review Board.
SNP genotyping of 620,901 markers on ADNI-1 participants were generated
using Illumina BeadStudio 3.2 software from bead intensity data. All SNP
genotypes are publicly available for download at the ADNI website. For genotype
imputation analysis, only SNPs fulfilling the following criteria were included (1)
per-SNP call rate ≥ 0.98; (2) minor allele frequency (MAF) ≥ 0.01; (3) P-value for
Hardy-Weinberg equilibrium (HWE) ≥ 10–6 in our sample set. Imputation was
performed using the software MACH-ADMIX42 using the 1000 Genomes Project
Phase 3 V.5 (http://www.internationalgenome.org) as a reference panel. We
excluded SNPs with R2 < 0.3, MAF < 0.01 and all INDELs from the imputed
genotype data to obtain genotypes for 7,512,167 SNPs for subsequent association
analyses.
MRI analysis and extraction of imaging phenotypes. Dr. Christos Davatzikos’
group from University of Pennsylvanian analyzed the baseline MRI T1 scans of
ADNI1 participants and generated the 145 ROIs spanning the entire brain by using
the Multi-atlas region Segmentation (MUSE) framework43. In this framework,
multiple atlases with semi-automatically extracted ground-truth ROI labels were
first warped individually to the target image using non-linear registration
methods44,45. To fuse the ensemble into a final segmentation, they adopted a spatial
adaptive weighted voting strategy, in which a local similarity term was used for
ranking and weighting ground truth labels from different atlases and an image
intensity based term was used for modulating the segmentations at the boundaries
of the ROIs according to the intensity profile of the subject image43. In validation
experiments, the multi-atlas approach was showed to achieve significantly higher
accuracy in comparison to single-atlas based segmentation43. In this study, we
downloaded the volume measures of ROIs from ADNI.
ROI-wise genome-wide association analysis in ADNI1. Autosomal chromosome
SNP associations for volumes from 145 ROIs spanning whole brain were assessed
by linear regression under the assumption of an additive genetic model. All models
were adjusted for age, gender, education, handedness and 3 principal components
to control population stratification. The genomic control for 145 GWASs ranged
between 0.98 to1.02.
Genetic correlation network analysis of brain ROIs in ADNI1. In multivariate
quantitative genetics, a genetic correlation (rg) is the proportion of variance that
two traits share due to additive genetic effects, which estimates the degree of
pleiotropy or causal overlap12,14,46. The cross phenotype association analysis
(CPASSOC) is a method proposed to integrate association evidence of multiple
traits from multiple GWAS and detect cross-phenotype associations13. Thus,
CPASSOC analysis of genetic correlated AD-related brain imaging traits could
improve power to identify genetic variants associated with multiple AD-imaging
traits. To identify groups of highly genetic correlated ROIs, we used the estimated
pairwise ROI genetic correlations to define the brain genetic correlation network.
In this network, nodes are brain ROIs while edges are estimated genetic correla-
tions between ROIs. To extract modules from this network, we adopted a weighted
gene co-expression network analysis (WGCNA) framework and used the method
of topological overlap matrix (TOM) elements in hierarchical clustering to identify
modular structures47. A flowchart for constructing a ROI genetic correlation net-
work, extracting network modules and identifying genetic variants associated with
modules using CPASSOC is presented in Supplementary Fig. 1a.
Pairwise ROI genetic correlations were estimated by the technique of cross-trait
LD score regression method14 using the GWAS summary statistics of ROIs. For
10,400 pairs among 145 ROIs, genetic correlations were not correctly estimated for
3,255 pairs because the estimated values were either “NA”, above 1 or below −1,
which might be driven by the small sample size, and these pairs were then filtered
out. However, this filter may reduce power to identify variants associated with
ROIs. The pairwise genetic correlations are presented in Supplementary Fig. 1 and
we observed high genetic correlations among the ROIs.
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We used the ROI genetic correlation matrix and power adjacency function47 to
generate network adjacent matrix:
aij ¼ rgij






β ð1Þ
while rgij is the genetic correlation between nodes ROI i and ROI j, and aijis the
connection strength between two nodes.
To choose the parameter β and genetic correlation P-value threshold, we used
the scale-free network model to construct an image network. The scale-free
network assumes that most nodes in a network are sparsely connected with the
exception of a few hub nodes that are densely connected with other nodes48. In the
scale-free network models, more connections are likely to occur for those hub
nodes with already-high connectivity, which meet biological criteria47,48. We used
the power law pðkÞ  kγto estimate the scale-free property, where k is the
connectivity for each node and equals the number of its direct connections to other
node. To generate the network, we assessed different power adjacency function
parameter β= 2, 4, 6 and 8 and filtered the genetic correlation with different
genetic correlation (rg) P-value thresholds of 0.5, 0.3, 0.2 and 0.1. For each P-value
threshold, if the estimated genetic correlation P-value was larger than that, we set
the genetic correlation to be 0. Using the four thresholds, we generated different
networks for β= 2, 4, 6 and 8 and accessed their corresponding scale-free topology
using linear regression model fitting index R2between log10(p(k)) and log10(k) for
all nodes. We observed that a P-value threshold of 0.2 with β= 6 corresponded a
network with the scale-free topology and had the largest R2of 0.61. The histogram
of connectivity k and scale-free topology plots for networks with β= 6 and
different P-value threshold were showed in Supplementary Fig. 2. Thus, we used
the network adjacent matrix generated under this criterion for further analysis. In
this network, 40 out of 145 ROIs had k equal to 0 and 105 ROIs were carried out in
module identification analysis.
We adopted the methods introduced by WGCNA framework47 to identify
network modules. The adjacent matrix was transformed into a topological overlap
matrix (TOM) with element defined as
wij ¼
lij þ aij
min ki; kj
n o
þ 1 aij
ð2Þ
where lij ¼
P
u aijauj and ki ¼
P
u aiuis the node connectivity.
TOM based dissimilarity measure was generated by
dwij ¼ 1 wij ð3Þ
This dissimilarity matrix was used as the input for average linkage hierarchical
clustering. The hierarchical clustering grouped the closet ROIs and formed the
branches to identify module. For the genetic correlation network, we identified 16
modules spanning the whole brain with the largest module containing 17 ROIs and
the smallest containing 3 ROIs (Supplementary Fig. 2).
CPASSOC analysis within modules. We applied the CPASSOC package devel-
oped by Zhu et al.13 to combine association evidence of ROIs within each module.
CPASSOC can integrate association evidence from summary statistics of multiple
traits and improves power when variant is associated with at least one trait.
CPASSOC provides two statistics, SHom and SHet. SHom is similar to the fixed effect
meta-analysis method49 but accounting for the correlation of summary statistics
among cohorts induced by potential overlapped or related samples. In brief,
assuming we have summary statistical results of GWAS from J cohorts with K
phenotypic traits. In each cohort, single SNP-trait association was analyzed for
each trait separately. Let Tjk be a summary statistic for a SNP, jth cohort and kth
trait. Let T ¼ ðT11;    ;TJ1;    ;T1K ;    ;TJK ÞT represents a vector of test statistics
for testing the association of a SNP with K traits. Let
β ¼ β11;:::;βJ1;:::;β1K;:::;βJK
 T
be the effect sizes of the SNP. The null hypothesis is
H0: β=0 and the alternative hypothesis H1 is that at least one of the elements of β is
not equal to zero. We used a Wald test statisticTjk ¼ bβjk=bsjk , where β^jk and s^jk are
the estimated coefficient and corresponding standard error for the kth trait in the jth
cohort. It is reasonable to assume that T follows a multivariate normal distribution
with mean 0 and correlation matrix R under the null hypothesis. When the effect is
homogeneous, the most powerful test statistic SHom is defined as
SHom ¼
eT ðRWÞ1TðeT ðRWÞ1TÞT
eT ðWRWÞ1e ð4Þ
which follows a χ2 distribution with one degree of freedom, where eT ¼ ð1; :::; 1Þ
has length J × K and W is a diagonal matrix of weights for the individual test
statistics. We used the sample sizes for the weights, wjk ¼ ffiffiffiffinjp , nj is sample size of
the jth cohort.
To further allow for different effect directions of a variant for different traits in
different cohorts, we define SHet. We first let
SðτÞ ¼ e
T RðτÞWðτÞð Þ1TðτÞ RðτÞWðτÞð Þ1TðτÞÞT
eTWðτÞ1RðτÞ1WðτÞ1e ð5Þ
Where T(τ) is the sub-vector of T satisfying Tjk





>τ for a given τ>0, R τð Þis a
sub-matrix of R representing the correlation matrix, and W τð Þbe the diagonal
submatrix of W, corresponding to T τð Þ. The test statistic is then
SHet ¼ maxτ>0 SðτÞ ð6Þ
The asymptotic distribution of SHet does not follow a standard distribution but can
be evaluated using simulation. SHet is an extension of SHom but power can be
improved when the genetic effect sizes vary for different traits. The distribution of
SHet under the null hypothesis can be obtained through simulations or
approximated by an estimated beta distribution.
We applied both SHom and SHet to combine summary statistics for ROIs within
each module. The CPASSOC analysis of multiple genetic correlated traits in
identified module would allow us to identify variants that are likely to be missed by
conventional GWAS of single trait and reduce the multiple comparison burden in
the genetic analysis of hundreds of neuroimaging traits. Finally, we identified 15
loci with CPASSOC test P-value less than 1 × 10–7 in nine modules (Supplementary
Table 1). Importantly, three previously reported AD-associated SNPs, rs429358,
rs2075650 and rs439401 and the FAM222A SNP rs117028417 were exclusively
found in one module, which were green colored in Supplementary Fig. 1M and
Supplementary Table 1. The Manhattan plots and Q-Q plots of CPASSOC analysis
and single ROI GWAS for this module were showed in Fig. 1 and Supplementary
Fig. 2.
Genetic analysis of AV-45 PET imaging. 18F-Florbetapir (AV-45) PET imaging
was performed at baseline and 2-year follow-up for participants enrolled in the
ADNI GO and two phases22. UC Berkeley extracted weighted AV-45 standardized
uptake value ratio (SUVR) means for four main cortical regions: frontal, anterior,
and posterior cingulate, lateral parietal and lateral temporal regions (version
2019.4.12) for ADNI-GO2 participants. They also calculated composite SUVR for
cortical which is weighted SUVR mean in frontal, cingulate, parietal and temporal
regions. These data can be downloaded from the ADNI database. We used the
SUVR mean of composite region including whole cerebellum, pons/brainstem and
eroded white matter as reference. Mean AV-45 SUVR of frontal, cingulate, lateral
parietal, lateral temporal and composite cortical relative to the reference were
calculated. The annual percent change in SUVR means at 2-year follow-up com-
pared to baseline was used as the main quantitative phenotype for genetic analysis.
The annual percent changes in AV-45 SUVR for all five brain regions were
approximately normally distributed (Supplementary Fig. 20). We collected 369
individuals with both SUVR measures for baseline and 2-year follow-up and
whole-genome sequencing data. The samples included 120 healthy people, 26
people with AD, 64 people with late mild cognitive impairment (LMCI) and 159
people with early mild cognitive impairment (EMCI) diagnosed at baseline. The
samples characteristics and demographics for samples are shown in Supplementary
Table 11.
WGS data from 817 ADNI participants were downloaded from the ADNI
dataset. WGS was performed using blood-derived genomic DNA samples and
sequenced on the Illumina HiSeq2000 using paired-end read chemistry and read
lengths of 100 bp at 30–40X coverage50. As previously described using Broad
GATK and BWA-mem, reads were mapped and aligned to the human genome
(build 37), then variants were called50,51.
For single SNP association test, association test of SNP rs117028417 with
phenotypes were performed using linear regression under an additive genetic
model in PLINK. Baseline age and gender were included as covariates. For gene-
based association test, we extracted 8 and 6 functional coding variants defined as
missense, in frame deletion/insertion, stop gained/lost, start gained/lost, splice
acceptor/donor, or initiator/start codon for FAM222A and TRPV4 respectively. All
of those variants are rare with minor allele frequency (MAF) < 0.01 in ADNI
samples. Gene-based association tests were performed using burden and SKAT52,
adjusting age and sex as covariates.
Genetic analysis of CSF Aβ and Tau. Collection and processing of ADNI CSF
samples was described in the ADNI procedures manual (http://www.adni-info.org/).
We downloaded UPENNBIOMKs dataset.csv file from ADNI website. We col-
lected 617 individuals with both CSF Aβ42, tTau and pTau at baseline level and
WGS data. For baseline data, since raw CSF biomarkers were skewed or bimodal
skewed distributed, rank normal transformations were conducted for each bio-
marker separately (Supplementary Fig. 21a–f). To conduct CSF biomarkers long-
itudinal change genetic association, we collected 274 individuals with both baseline
and 24-month follow-up CSF biomarkers and WGS data. The CSF biomarkers raw
data at baseline and 2-year follow-up in 218 individuals were used to calculate
annual changes in Aβ42, tTau and pTau separately. The annual changes of three
CSF biomarkers were approximately normally distributed (Supplementary
Fig. 21g–i). The samples characteristics and demographics for CSF biomarker traits
association analysis are shown in Supplementary Tables 12, 13.
Association test of SNP rs117028417 with phenotypes were performed using
linear regression under an additive genetic model in PLINK. Baseline age and sex
were included as covariates. We extracted 8 and 15 coding variants defined as
missense, in frame deletion/insertion, stop gained/lost, start gained/lost, splice
acceptor/donor, or initiator/start codon for FAM222A and TRPV4 respectively
(Supplementary Table 4). All of those variants are rare with minor allele frequency
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(MAF) < 0.01 in ADNI samples. Gene-based association tests were performed
using burden and SKAT52, adjusting age and sex as covariates.
Analysis of FAM222A mRNA in AD. The development of the Mount Sinai Brain
Bank (MSBB) cohort was described in the previous studies35,53. MSBB is a large
AD cohort and now holds over 2,040 well-characterized human brains53. The
datasets we used assessed a total of 125 human brains which was assembled after
applying stringent inclusion/exclusion criteria and represents the full spectrum of
cognitive and neuropathological disease severity35. Detailed sample demographic
information and description of the cognitive and neuropathological traits can be
seen in previously published paper by Dr. Bin Zhang’s lab35. We downloaded the
normalized microarray data of MSBB Array Tissue Panel Study from the Synapse
at http://www.synapse.org/#!Synapse:syn3157699. The RNA samples from 19 brain
regions isolated from 125 MSBB specimens were collected and profiled on the
Affymetrix 133AB and Affymetrix 133Plus2 platforms. RNA quality was assessed
using a combination of a 260/280 ratio derived from resolution electrophoresis
system (LabChipTM, Agilent Technologies, Palo Alto, CA, USA) and 3′–5′
hybridization ratios for GAPDH probes35. Not all brain regions for all subjects
were available for analysis. There was an approximately 60 samples (40 AD, 20
controls) per brain region available for analysis. The array probes were annotated
according to the Ensemble version 72 (genome build GRCh37) using the R/Bio-
mart library. The raw microarray data were quantile normalized with all probe sets
on the arrays using RMA54 method implemented in the R/Bioconductor package
affy (v1.44) with the default parameters. The data were then corrected for cov-
ariates including sex, postmortem interval (PMI), pH and race using a linear
regression model. The FAM222A gene expression data was identified by probe set
226487_at. The processed FAM222A mRNA level means for groups of AD and
control were compared using two-sided Welch t-test using R.
Association analysis of FAM222A DNA methylation. We downloaded two
datasets, E-GEOD-45775 and E-GEOD-76105, with DNA methylation profiling
from the European Bioinformatics Institute (EMBL-EBI) ArrayExpress website
https://www.ebi.ac.uk/arrayexpress/. Samples of dataset E-GEOD-45775 included 5
controls, 5 AD Braak stage I-II and 5 AD Braak stage V-VI (Supplementary
Table 14). The methylation values were adjusted and normalized using BeadStudio
software v3.2 to obtain normalized beta and average Beta detect P-value. The array
used the HumanMethylation27_270596_v.1.2 design and one methylation site
cg01335367 was identified located on chr12:109734355–109734404 (GRCh38.p12),
associated with FAM222A. We analyzed the association between methylation in
cg01335367 with AD using logistic regression and adjusted for sex. We also per-
formed one-way analysis of variance (ANOVA) to determine differences between
methylation levels of control and different Alzheimer Braak stage groups. Study E-
GEOD-70615 investigated DNA methylation profiling in the superior temporal
gyrus (STG). Samples included 34 AD and 34 non-demented controls, which had
52 European, 8 Hispanic, 6 African, 1 Asian Americans and 1 unknown (Sup-
plementary Table 15). The Beta values from the probes were quantile normalized
using lumi package in R. We performed association analysis in 52 European
Americans only. The association between methylation in those sites with AD were
analyzed using logistic regression model adjusting age, gender and estimated cel-
lular proportions (neuronal vs. glial).
Mice and human tissues. Mouse surgery and procedures were performed
according to the NIH guidelines and were approved by the Institutional Animal
Care and Use Committee (IACUC) at Case Western Reserve University. 5xFAD
transgenic mice (B6.Cg-Tg(APPSwFlLon, PSEN1*M146L*L286V) 6799Vas/
Mmjax, JAX#008730) were purchased from the Jackson Laboratory. The use of all
human tissue samples was approved by the University Hospitals Institutional
Review Board (IRB) for human investigation at University Hospitals Case Medical
Center at Cleveland. Human brain tissues obtained postmortemly from University
Hospitals of Cleveland were fixed, and 6-μm-thick consecutive sections were
prepared. The information of fixed or frozen human tissues were listed in Sup-
plementary Tables 16, 17.
Immunocytochemistry, immunofluorescence and immunoblot. Immunocy-
tochemistry was performed by the peroxidase anti-peroxidase protocol. Taken
briefly, paraffin embedded brain tissue sections were first deparaffinized in xylene
and rehydration in graded ethanol and incubated in Tris Buffered Saline (TBS,
50 mM Tris-HCl and 150 mM NaCl, pH 7.6) for 10 min before antigen retrieval in
1X Immuno/DNA retriever with citrate (BioSB, Santa Barbara, CA) under pressure
using BioSB’s TintoRetriever pressure cooker. Sections were rinsed with distilled
H2O, and blocked with 10% normal goat serum (NGS) in TBS at room temperature
(RT) for 30 min. Tissue sections were further incubated with primary antibodies in
TBS containing 1% NGS overnight at 4 °C, and immunostained by the peroxidase-
antiperoxidase based method. For double Immunofluorescence staining, paraffin
embedded tissue sections were deparaffinized in xylene and re-hydrated in graded
ethanol without H2O2 incubation as described above. The sections were incubated
in phosphate buffered saline (PBS) at RT for 10 min followed by block with 10%
NGS in PBS for 45 min at RT. The sections were incubated with primary antibodies
in PBS containing 1% NGS overnight at 4 °C. After being washed with 1% NGS in
PBS for 10 min, the sections were incubated in 10% NGS for 10 min and followed
by three quick washes with 1% NGS in PBS. Then, the sections were incubated with
Alexa Fluor 488 or 568 dye labeled secondary antibodies (1:300, Invitrogen,
Carlsbad, CA) for 2 h at RT in dark, washed three times with PBS, stained with
DAPI, washed again with PBS for three times, and finally mounted with
Fluoromount-G mounting medium (Southern Biotech, Birmingham, AL). For
thioflavin-S staining, slides were incubated with 1% thioflavin-S (Santa Cruz Bio-
technology, Dallas, TX) for 8 min, washed 2 times with 80% ethanol, and 1 time
with 95% ethanol and PBS, then stained with DAPI. For immunoblot, human or
mice tissue samples were all lysed with TBS plus 1 mM phenylmethylsulfonyl
fluoride (PMSF) (Millipore, Burlington, MA), protease inhibitor cocktail (Sigma
Aldrich, St. Louis, MO) and phosphatase inhibitor cocktail (Sigma Aldrich, St.
Louis, MO). Equal amounts of total protein extract were resolved by SDS-PAGE
and transferred to Immobilon-P (Millipore, Burlington, MA). Following blocking
with 10% nonfat dry milk, primary and secondary antibodies were applied and the
blots developed with Immobilon Western Chemiluminescent HRP Substrate
(Millipore, Burlington, MA). Images were taken by ChemiDoc Touch Imager (Bio-
rad, Hercules, CA). Primary antibodies used in this study are listed in Supple-
mentary Table 18. The dilution of antibodies used for IF or IHC. 4G8 (BioLegend,
SIG-39220; IF, 1:1000), 6E10 (BioLegend, 803001; IF and IHC, 1:1000), 82E1 (IBL,
10323; IF, 1:1000), Aggregatin (Abcam, ab122626; IF/IHC, 1:100), Aggregatin
(LifeSpan BioSciences, LS-C170630; IHC, 1:1000), Aggregatin (Aviva Systems
Biology, ARP69038_P050; IHC, 1:1000), Flag (Sigma Aldrich, F1804; IF/IHC,
1:1000), Flag (Thermo Fisher, PA1–984B; IHC, 1:200), Flag (Cell Signaling
Technology, 2368; IHC, 1:200), Flag-HRP (Proteintech, HRP-66008; IHC, 1:1000),
GFP (Abcam, ab32146; IHC, 1:500), Myc (Thermo Fisher, MA1–21316; IHC,
1:1000), Myc (Cell Signaling Technology, 2276; IHC, 1:500), and Nu4 (Klein lab,
IF/IHC, 1:2000). All uncropped and unprocessed blots are provided in the Source
Data file (Source Data for Statistics and Blots).
Expression vectors and recombinant proteins. pcDNA3.1(+) (Invitrogen,
Carlsbad, CA) plasmid was modified to express recombinant proteins to express
recombinant proteins containing a 4xFlag-Twin-Strep-tag at their N-terminal. The
cDNA of full length or truncated human Aggregatin were inserted into the
modified pcDNA3.1(+) plasmid. All primers and cDNA constructs used in this
study are listed in Supplementary Data 1 and Supplementary Table 19. Eight
micrograms plasmid was used to transfect one 10 cm dish of Lenti-293T cells with
TransIT®−293 Transfection Reagent (Mirus, Madison, WI). Cells were collected at
24 h after transfection and lysed by lysis buffer (100 mM Tris-HCl, 150 mM NaCl,
1 mM EDTA and 1% NP40, pH 8.0) containing 1 mM PMSF (Millipore, Bur-
lington, MA), protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO) and
phosphatase inhibitor cocktail (Sigma Aldrich, St. Louis, MO). The lysate was
centrifuged at 14,000 g for 15 min at 4 °C. Supernatant was incubated with Mag-
Strep type3 XT beads (IBA Lifesciences, Goettingen, Germany) overnight at 4 °C.
Beads were washed three times with lysis buffer, and eluted with BXT buffer (IBA
Lifesciences, Goettingen, Germany) overnight at 4 °C. At last, the eluted recom-
binant proteins were subjected to dialysis using 10 kD Slide-A-Lyzer™ Dialysis
Cassettes (Thermo Fisher Scientific, Waltham, MA), concentration with 10 kD
Spin Column (Abcam, Cambridge, MA) and purification by size-exclusion
chromatography.
Stereotaxic injection and ICV infusion. Mice surgery were performed according
to the NIH guidelines and were approved by the Institutional Animal Care and Use
Committee (IACUC) at Case Western Reserve University. All AAVs with 1013
genome copies per mL (GC per mL) were obtained from Vigene Biosciences (Jinan,
China). For stereotaxic injection, mice were anesthetized with isoflurane and
immobilized using the stereotactic frame equipped with a heating blanket to
maintain body temperature throughout the procedure. After hair removal and the
cleaning of the shaved area with betadine and alcohol, mice were injected with
bupivacaine/lidocaine and a small incision was made to expose the skull surface.
Two small holes were drilled in the skull (relative to bregma: anteroposterior
−2.1 mm, medial lateral ±2 mm; Note that ± is the plus-minus sign throughout this
study) followed by injection of 2 μl AAVs using Hamilton syringes into the hip-
pocampal CA1 at dorsal ventral −1.45 mm. Injection speed was pump controlled at
0.2 μl per min. The needle was left in place for 5 min before it was slowly with-
drawn. For ICV infusion, the mini-osmotic pump (Model 1004, Alzet, Cupertino,
CA; flow rate of 0.11 μl per hour, 28 days) and brain infusion cannula attached with
2.5–3 cm catheter tubes (Brain infusion kit 3, Alzet, Cupertino, CA) were filled with
recombinant protein in artificial cerebrospinal fluid (aCSF), followed by pump
incubation in aCSF at 37 °C for 48 h according to the manufacturer’s instructions.
For implant surgery, a hole was drilled in the skull (relative to bregma: ante-
roposterior −0.5 mm, medial lateral 0.75 mm). The cannula was positioned on the
skull with the needle plug 2.5 mm into the ventricle. The cannula was fixed and
secured by cyanoacrylate glue.
Behavioral tests. Mice behavioral tests were also performed according to the NIH
guidelines and were approved by the Institutional Animal Care and Use Committee
(IACUC) at Case Western Reserve University. The Barnes maze consisted of a white
acrylic circular disk 92 cm in diameter with 20 equally spaced holes (5 cm in
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diameter) located 2 cm from the edge of the disk. The maze was illuminated by two
60W lamps to provide an aversive, bright disk surface. An acrylic escape box (7 × 7 ×
5 cm) could be fitted under any of the holes in the maze. The maze was raised 30 cm
from the floor and rested on a pedestal that enabled it to be rotated 360° on a
horizontal plane. An acrylic start bin with 15 cm diameter and 15 cm height was used.
Trials were recorded using a webcam and analyzed by video tracking software
(EthoVision XT, Noldus, Leesburg, VA). Each trial began with the start bin positioned
in the center of the maze with the mouse placed inside. The mouse remained in the
start bin for 30 s, providing a standard starting context for each trial and ensuring that
initial orientation of the mouse in the maze varied randomly from trial to trial. Each
mouse was allowed to explore the maze freely for 2min. After the mouse entered the
escape hole, the mouse was left in the escape box for 90 s before being returned to its
home cage. If the mouse did not enter the escape box within 120 s, it was gently
picked up by the experimenter and placed over the target hole and allowed to enter
the escape box. After each trial, the maze and escape box were cleaned carefully with a
10% alcohol solution to dissipate odor cues and provide a standard olfactory context.
Five training sessions consisting of two trials each were run on subsequent days and
escape latencies were measured. For Y maze test, mice were placed in a Plexiglas Y
maze (with arms 60 cm in length) and allowed to explore the maze freely for 10min.
When put in the Y maze, the mice were recorded using the ANY-maze tracking
system, and the time and frequency in the spontaneous alteration ratio were counted
automatically. All tests were performed at the Case Behavior Core, with the investi-
gator blinded to mouse genotype.
Plaque isolation. Amyloid plaque cores were isolated as previously described55.
Briefly, whole mouse brain or human brain gray matters were homogenized, boiled
in lysis buffer (2% SDS, 50 mM Tris-HCl pH 7.5, 50 mM DTT), and centrifuged at
100,000 g for 1 h at 10 °C. The pellet was solubilized in fraction buffer (1% SDS, 50
mM Tris-HCl pH 7.5, 50 mM DTT) and centrifuged at 100,000 g for 1 h at 10 °C.
The pellet was further suspended in fraction buffer and loaded on top of a dis-
continuous sucrose gradient (1.0, 1.2, 1.4 and 2.0 M sucrose in 50 mM Tris pH 7.5
containing 1% SDS), centrifuged at 220,000 g for 20 h at 10 °C and fractionated into
sixteen fractions (300 µl per fraction). Plaque-core-enriched fraction #13 were
further diluted in fraction buffer and centrifuged at 220,000 g for 2 h at 10 °C. The
resulting pellet was dissolved in 70% formic acid and subsequently dried using a
SpeedVac system. Solubilized proteins were further resuspended in 1X SDS sample
buffer with 8M Urea.
Aβ preparation, pull-down, and co-sedimentation assay. Synthetic human
Aβ1–42 and Aβ1–40 peptides (GL Biochem, Shanghai) were dissolved in hydroxyl-
fluro-isopro-panol (HFIP) and subsequently dried using a SpeedVac system. Both
Aβ1–42 and Aβ1–40 monomers were prepared by dissolving the lyophilized Aβ in
dimethyl sulfoxide (DMSO) at 5 mM, sonicated for 10 min and diluted in PBS
buffer (NaCl 137 mM, KCl 2.7 mM, Na2HPO4 10 mM, KH2PO4 1.8 mM, pH 7.4) to
different concentrations. Aβ1–42 oligomers were prepared in DMSO/PBS and oli-
gomerized by incubation at 4 °C for 24 or 48 h. Monomeric or oligomer Aβ1–40
(100 μM) and Aβ1–42 solutions (50 μM) supplemented with or without rAggregatin
bound Strevdin-avdin beads were incubated in IP buffer (NaCl 300 mM, KCl
2.7 mM, Na2HPO4 10mM, KH2PO4 1.8 mM, pH7.4) at RT with shaking for 2 h.
After 4 times wash with IP buffer, beads were eluted by 1XSDS sample buffer (32.9
mM Tris-HCl pH6.8, 13% Glycerol, 1% SDS and 0.005 % bromophenol blue) and
analyzed by 10–20% SDS/Tricine protein gels (Invitrogen, Carlsbad, CA). For
Aβ1–42 oligomer formation and co-sedimentation assay, HFIP dissolved synthetic
Aβ1–42 peptides were solubilized in 30 mM NaOH to a final concentration of
100 μM, diluted to 2.5 μM in PBS and incubated with and without 30 nM rAg-
gregatin at 37 °C for different time points. After 10-minute centrifuge at 14,000 g,
pellets and supernatants were collected and analyzed by 10–20% SDS/Tricine
protein gels (Invitrogen, Carlsbad, CA).
Dynamic light scattering. Dynamic light scattering (DLS) experiments were
carried out with DynaPro™ instrument from Wyatt technology with a wavelength
of 633 nm and a scattering angle of 173°. The measurements of Aggregatin or
Aggregatin Δ61–80 at 100 nM were performed at 25 °C after 2 min equilibration
with correlation times defined on 10 s per run with 30 runs for each measurement.
The results were plotted as intensity of distribution (%) of particles versus
hydrodynamic radius (nm).
Circular dichroisms. The spectra were recorded over a wavelength range of
260–190 nm with standard sensitivity at the 50 nm per min scan speed with 1‐nm
resolution and 1‐s time constant at room temperature using a spectropolarimeter
(Jasco J-815). All the proteins were dissolved in phosphate buffer (pH8.0). The final
concentration of all samples was 1 µM. The secondary structure content was cal-
culated from the Circular dichroisms (CD) spectra using the online software K2D3.
Surface plasmon resonance. Surface plasmon resonance (SPR) was determined
using BIAcore3000 (GE Healthcare Life Sciences, Pittsburgh, PA). rAggregatin
(0.1 mg per ml) was immobilized on the CM5 sensor surface (GE Healthcare Life
Sciences, Pittsburgh, PA) in 10 mM acetate buffer (pH= 4.5). Running buffer was
1% DMSO in PBS-P buffer (0.02M phosphate, 2.7 mM KCl, 137 mM NaCl and
0.05% Tween 20). Binding of a dilution series comprising Aβ1–42 monomers to
rAggregatin was analyzed and fitted to the 1:1 binding model using BIAevaluation
software (GE Healthcare Life Sciences, Pittsburgh, PA).
Solid phase binding assay. rAggregatin was coated onto Nunc MaxiSorp 96-well
plates (Thermo Fisher Scientific, Waltham, MA) at 0.1 μg per well in PBS at 4 °C
overnight. After blocking in 1% BSA in PBS for 2 h at RT, Aβ1–42 at 6.25, 12.5, 25,
50, 100, or 200 nM or Aβ1–40 at 0.5, 1, 2, 4, or 8, or 16 μMmonomers were added to
the plates at 4 °C overnight. Plates were washed with PBS 4 times and incubated
with 6E10 antibody at 4 °C overnight, followed by 4 times PBS wash and devel-
opment in TMB solution (Thermo Fisher Scientific, Waltham, MA). The reaction
was stopped by sulfuric acid and assessed using a Synergy H1 microplate reader
(BioTek, Winooski, VT). Likewise, 0.2 μg Aβ1–42 or Aβ1–40 monomers were
immobilized on plates and incubated with 3.125, 6.25, 12.5, 25, 50, or 100 nM
rAggregatin. Bound rAggregatin were detected by an anti-Flag antibody and
developed in TMB solution as described above.
ThT fluorescence assay. HFIP treated Aβ1–40 or Aβ1–42 peptides were solubilized
in 30 mM NaOH to a final concentration of 400 μM, sonicated for 5 min in a water
bath and stored at −80 °C until further use. To monitor Aβ1–40 and Aβ1–42
fibrillization, a ThT assay was performed according previous studies56,57. Briefly, a
stock solution of Aβ was diluted to in PBS with 20 μM ThT. Then rAggregatin were
added at desired concentrations to the final volume of 100 µl. All samples were
transferred to a black 96-well nonbinding Surface microplate with clear bottom
(Corning, Corning, NY), and sealed with a polyester-based sealing film (Corning,
Corning, NY). Samples were incubated at 37 °C with stirring. Real-time ThT
fluorescence was measured every 5 min for at least 12 h at the excitation and
emission wavelengths of 446 nm and 482 nm respectively by a Synergy H1
microplate reader (BioTek, Winooski, VT).
Aβ1–42 aggregates stained by Thio-S. To evaluate Aβ aggregates formed in vitro,
rAggregatin (30 nM) and 2.5 μM Aβ in PBS were incubated at 37 °C for 4 weeks.
20 μl of protein solution were applied to the glass slides and completely air dry for
30 min. After washing with PBS, the samples were stained by 1% Thio-S for 10 min.
The 3D confocal images were analyzed by using Imaris (Bitplane, Concord, MA)
and the structure surface were extracted by using the SURFACE tools following the
manufacturer’s instructions.
Negative electric microscopy. HFIP dissolved synthetic Aβ1–42 peptides were
solubilized in 30 mM NaOH to a final concentration of 100 μM. Then diluted to
2.5 μM in PBS and incubated with and without 30 nM rAggregatin at 37 °C.
Immediately following the indicated incubation time, 20 μl of protein solution were
applied to the support surface of the grids, which were autoclaved by UV irra-
diation overnight. The grids were washed with 20 μl droplets of water 4 times,
followed by a 20 μL droplet of uranyl acetate solution, then examined in an FEI
Tecnai Spirit (T12) with a Gatan US4000 4kx4k CCD.
Total Aβ measurement by ELISA. Brains were homogenized in TBS Buffer
(50 mM Tris-HCl and 150 mM NaCl, pH 7.6) containing 1 mM PMSF (Millipore,
Burlington, MA), protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO) and
phosphatase inhibitor cocktail (Sigma Aldrich, St. Louis, MO). Total protein
concentrations were determined using the BCA kit (Thermo Fisher Scientific,
Waltham, MA). ELISA of total Aβ was carried out in 96-well high-binding
microtiter plates. Monoclonal antibody 6E10 raised against residues Aβ1–16 was
used as a capture antibody (diluted in PBS pH 7.4) and incubated over night at 4 °
Cin a humid chamber. After removal of the capture antibody, the plate surface was
blocking with 1% BSA for 1.5 h. After washing with PBS, 0.5 µg total protein were
added and incubated at 4 °Covernight. Monoclonal antibody MOAB-2 coupled to
horseradish peroxidase diluted in PBS were used as secondary antibodies and again
incubated over night at 4 °C. After three times washing with PBS, 100 μl of TMB
ELISA peroxidase substrate (Thermo Fisher Scientific, Waltham, MA) was added
and incubated for 1–10 min at RT in darkness. The reaction was stopped with 100
μl 2 M H2SO4 and absorbance was measured in a microplate reader at 450 nm. For
generation of standard curves, synthetic Aβ1–42 peptides freshly dissolved in
DMSO from 1 ng per µL to 10 pg per µL.
Isolation of exosomes. Lenti-293T cells were transfected with empty vector or
pCDNA-4xFlag-Aggregatin using TransIT®−293 Transfection Reagent (Mirus,
Madison, WI). Twenty-four hours after transfection, cells were cultured in the
DMEM medium supplemented with exosome-free FBS. Forty-eight hours later, the
cell culture medium was collected and centrifuged at 300 g for 15 min to remove
cells and debris. The supernatant was further filtered through a 0.22 μm filter and
centrifuged at 100,000 g for 2 h at 4 °C. The pellets enriched with exosomes were
resuspended in the lysis buffer (100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA
and 1% NP40, pH 8.0) containing 1 mM PMSF (Millipore, Burlington, MA),
protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO), and phosphatase
inhibitor cocktail (Sigma Aldrich, St. Louis, MO) followed by immunoblot analysis.
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Confocal microscopy and image analysis. All fluorescence images were imaged
on a Leica TCS SP8 gSTED confocal microscopy (Leica Microsystems, Buffalo
Grove, IL) equipped with a motorized super Z galvo stage, two PMTs, three Hyd SP
GaAsP detectors for gated imaging, and the AOBS system lasers including a 405
nm, Argon (458, 476, 488, 496, 514 nm), a tunable white light (470 to 670 nm), and
a 592 nm STED depletion laser. Series of confocal images with optical thickness of
300 nm were collected using the ×100 oil objective. All 3D confocal images of
plaque were reconstructed using Imaris (Bitplane, Concord, MA) after background
subtraction. Quantification of Aggregatin foci in plaques and measurement of
plaque load and size were performed with open-source image analysis programs
WCIF ImageJ (developed by W. Rasband).
Statistical analysis. Statistical analysis was done with one-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparison test or student-t-test using
GraphPad Prism (GraphPad, CA). Data are means ± SEM. p < 0.05 was considered
to be statistically significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available on request from the
corresponding author X.L.W. Case Western Reserve University supports the NIH
Guidelines for the Sharing of Research Resources including “the Sharing of Biomedical
Research Resources: Principles and Guidelines for Recipients of NIH Grants and
Contracts”. If any intellectual property is pursued, the data will be shared and distributed
following advice from the authorities of Case Western Reserve University. The source
data underlying Figs. 1, 2g, 2h, 3a–d, 3f, 3g, 4a–f, 5c–f, 5h–k, 5m–p, and Supplementary
Figs. 3a–e, 4, 5c–h, 7d, 7e, 7i–k, 8b, 8d, 9a–d, 10b, 10c, 10e, 11b–f, 12a, 12c–e, 13a–d,14,
15e–h, 16, 17b–d, 18b, 18c, 19a, 19c, and 19e are provided as a Source Data file. Source
Data for GWAS in Fig. 1: 10.6084/m9.figshare.11336657 (https://figshare.com/s/
2d59f2f0b7cfd04d31ca). Source Data for GWAS in Supplementary Fig. 2a: 10.6084/m9.
figshare.11336666 (https://figshare.com/s/c094e1a5c2ea562b6aef). Source Data for
GWAS in Supplementary Fig. 2b: 10.6084/m9.figshare.11337272 (https://figshare.com/s/
1449069e2b80a75b30cf). Source Data for GWAS in Supplementary Fig. 2c: 10.6084/m9.
figshare.11337281 (https://figshare.com/s/4cc10442ea2f51333cd7). Source Data for
GWAS in Supplementary Fig. 2d: 10.6084/m9.figshare.11337284 (https://figshare.com/s/
220153dbfce30bca2802). Source Data for GWAS in Supplementary Fig. 2e: 10.6084/m9.
figshare.11337290 (https://figshare.com/s/8a1f80899f69b462f284).
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